--- title: "Innovent is profitable at home. IBI363 decides its global story" url: "https://aibio.space/companies/innovent-biologics/desk-view/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-10-31" tickers: "HKEX:1801" summary: "Revenue rose 44.8% in the first half and cash topped RMB 30 billion. The next leg depends on a global lung cancer trial against docetaxel." --- Opinion Desk view by the aibio.space Innovent desk. Updated October 22, 2026. Every figure links to its source. This is analysis, not a recommendation to trade. [How desk views are written](https://aibio.space/disclosures/). Innovent Biologics ยท Opinion 2026-10-22 # Innovent is profitable at home. IBI363 decides its global story Revenue rose 44.8% in the first half and cash topped RMB 30 billion. The next leg depends on a global lung cancer trial against docetaxel. ## The technology Innovent is no longer a one-drug story. It has [20 marketed products, 13 of them on China's national reimbursement list](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0825/2026082500983.pdf), spanning cancer, obesity, cholesterol, eye disease and psoriasis. The anchors are sintilimab (TYVYT), a PD-1 antibody now approved for ten indications, and mazdutide, which Innovent calls the world's first approved glucagon/GLP-1 dual agonist for weight management and type 2 diabetes. The pipeline value sits in three assets the company says have entered or will soon enter global phase 3 trials. IBI363 is a PD-1 antibody fused to an IL-2 arm biased toward the alpha receptor, meant to wake up immune cells in tumors that no longer respond to PD-1 drugs. Arcotatug tavatecan (IBI343) is an antibody-drug conjugate aimed at CLDN18.2, a protein found on many gastric cancers. IBI324 is a VEGF/ANG2 eye drug partnered with Ollin Biosciences. Innovent puts their [combined addressable market above US$60 billion](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0825/2026082500983.pdf), a company estimate. ## The odds IBI363 is the biggest bet and still early in hard evidence. Long-term phase 1 data at ASCO showed [median overall survival of 18.2 months](https://www.prnewswire.com/news-releases/2026-asco--innovent-presents-long-term-follow-up-results-from-the-poc-study-of-ibi363-tak-928-pd-1il-2-bias-bispecific-fusion-protein-showing-robust-survival-benefits-in-advanced-immunotherapy-resistant-non-small-cell-lung-302786450.html) at 3 mg/kg in squamous lung cancer that had stopped responding to immunotherapy, from a China-only study without a control arm. The global MarsLight-11 phase 3 now tests it against docetaxel in both [squamous and non-squamous disease](https://www.prnewswire.com/news-releases/innovent-announces-expansion-of-global-phase-3-marslight-11-study-of-ibi363tak-928-alpha-biased-il-2pd-1-bispecific-fusion-protein-in-immunotherapy-resistant-nsclc-to-include-patients-with-non-squamous-nsclc-302890858.html). The BIO, Informa and QLS study found that [57.8% of phase 3 programs reach a filing](https://go.bio.org/rs/490-EHZ-999/images/ClinicalDevelopmentSuccessRates2011_2020.pdf) and that only 7.9% of drugs entering phase 1 reach approval. Arcotatug tavatecan has an open-label phase 3 trial in China and Japan, G-HOPE-001, that [met its primary endpoint at the first interim analysis](https://www.prnewswire.com/news-releases/worlds-first-cldn18-2-adc-for-regulatory-review-innovent-biologics-announces-ibi343-arcotatug-tavatecan-met-primary-endpoint-in-international-phase-3-study-in-advanced-refractory-gastric-cancer-and-nda-accepted-by-china-nmpa-302791220.html), and the Chinese filing has priority review. An IBI363 investigator noted in the ASCO release that several large phase 3 trials in lung cancer after chemotherapy and immunotherapy have not yet delivered satisfactory outcomes. ## The money The finances are strong. First-half 2026 total revenue was [RMB 8,617.8 million, up 44.8%](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0825/2026082500983.pdf), and product revenue rose 56.7% to RMB 8,201.5 million. IFRS profit rose 50.2% to RMB 1,253.1 million. Cash on hand was RMB 30.2 billion, about US$4.5 billion, as of July 31, 2026. Partners add more. Innovent said deals signed over ten months with Takeda, Eli Lilly, Pfizer, Ollin and Spero have an [aggregate potential value of about US$34 billion](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0825/2026082500983.pdf), most of it in milestones that may never be paid. The company targets RMB 35 billion to RMB 40 billion of revenue by 2030. ## The risks IBI363 has real toxicity at the dose being pushed forward. Grade 3 or worse treatment-emergent adverse events hit [64.9% of patients on 3 mg/kg](https://www.prnewswire.com/news-releases/2026-asco--innovent-presents-long-term-follow-up-results-from-the-poc-study-of-ibi363-tak-928-pd-1il-2-bias-bispecific-fusion-protein-showing-robust-survival-benefits-in-advanced-immunotherapy-resistant-non-small-cell-lung-302786450.html), against 30.6% at lower doses. A global phase 3 against docetaxel will show whether the survival tail holds up under randomization. Margins are slipping slightly as the mix widens: gross margin was [85.0% versus 86.0%](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0825/2026082500983.pdf) a year earlier, while research spending rose to RMB 1,683.7 million from RMB 1,008.8 million. Outside China, Innovent shares control of its best assets with partners. Takeda holds [ex-China rights to arcotatug tavatecan](https://www.prnewswire.com/news-releases/worlds-first-cldn18-2-adc-for-regulatory-review-innovent-biologics-announces-ibi343-arcotatug-tavatecan-met-primary-endpoint-in-international-phase-3-study-in-advanced-refractory-gastric-cancer-and-nda-accepted-by-china-nmpa-302791220.html) and co-develops IBI363. ## Our read Innovent has crossed into steady profit with fast growth and a large cash pile. The near-term story is execution in China: mazdutide, newly reimbursed drugs and a CLDN18.2 approval. The long-term story is whether IBI363 can win a global phase 3 in a setting where several large trials have not delivered. The ESMO gastric data and the first IBI363 melanoma readout, due by early 2027, are the next real tests. --- Source page: https://aibio.space/companies/innovent-biologics/desk-view/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Innovent is profitable at home. IBI363 decides its global story", 2026-10-31, https://aibio.space/companies/innovent-biologics/desk-view/